August 9, 2025

Efficacy of cenobamate in tumor-related epilepsy.

View Full Paper

Ask AI

Bookmark

Authors

GCGuido ChiribogaJacksonville College ASAdrian SafaJacksonville College AFAnteneh M. FeyissaJacksonville College

Discussion

Member takes

Implication

Retrospective study reports 56% reduction in seizure frequency in patients with tumor-related epilepsy, suggesting cenobamate may be an effective adjunctive treatment.

Key Points

Cenobamate treatment for tumor-related epilepsy resulted in a 56.3% reduction in median seizure frequency from 12 to 3 per month.
Out of 17 patients, 4 (23.5%) achieved seizure freedom and 7 (41.1%) were considered responders with at least 50% seizure reduction.
The study included patients from multiple centers and focused on those with drug-resistant seizure conditions, assessing treatment efficacy.
No adverse events were reported in patients taking concurrent chemotherapy, indicating a safety profile worth exploring further.

Cite This Study

Chiriboga et al. (2025) studied this question.

synapsesocial.com/papers/689dfea6d61984b91e13c8a6 https://doi.org/10.1002/epd2.70081

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study reports 56% reduction in seizure frequency in patients with tumor-related epilepsy, suggesting cenobamate may be an effective adjunctive treatment.

Efficacy of cenobamate in tumor-related epilepsy.

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy of cenobamate in tumor-related epilepsy.

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider